A Histomorphological Study of Urinary Bladder Lesions in a Tertiary Care Hospital
Abstract:
Urinary bladder lesions, both benign and malignant, are becoming more common in modern times. The urinary bladder is susceptible to a range of lesions, including benign tumors, malignant tumors, and non-neoplastic lesions. A lot of people either die or go through a lot of pain because of neoplastic bladder lesions. Understanding bladder tumors involve exploring their risk factors, which include smoking, occupational exposures, and chronic bladder irritation. In terms of genitourinary cancers, the most common ones are prostate and urinary bladder cancers. Bladder cancers are curable if diagnosed at an early stage. Cystoscopy to see the bladder mucosa and biopsy of any suspicious lesion and TURBT (transurethral resection of the bladder tumour) samples with histological evaluation are the most reliable methods for cancer diagnosis. Early and accurate diagnosis is crucial for effective management and improved patient outcomes. This case series presents cases with different urinary bladder lesions encountered in our tertiary referral hospital, providing insights into their presentation, diagnostic challenges, role of histopathology in making a diagnosis and thereby helping the clinician in exploring treatment options.
References:
[1].
Epstein,
J. I. (2010). The lower urinary tract and male genital system. In V. Kumar, N.
Fausto, J. C. Aster, & A. K. Abbas (Eds.), Robbins and Cotran
pathologic basis of disease (8th ed., pp. 971-1004). Elsevier.
[2].
Lenis,
A. T., Lec, P. M., Chamie, K., & Mshs, M. D. (2020). Bladder cancer: A
review. JAMA, 324(19), 1980-1991.
https://doi.org/10.1001/jama.2020.17598
[3].
Goyal,
V. K., Vyas, S. P., & Kothari, D. C. (2015). Spectrum of lesions in urinary
bladder biopsies: Histopathological study. International Journal of Dental
and Medical Research, 1(6), 42-46.
[4].
Pudasaini,
S., Subedi, N., Prasad, K. B. R., Rauniyar, S. K., Josi, B. R., & Bhomi, K.
K. (2014). Cystoscopic bladder biopsies: A histopathological study. Nepal
Medical College Journal, 6(1), 9-12.
[5].
Jecu,
M., Geavlete, B., Multescu, R., Stanescu, F., Moldoveanu, C., Adou, L., et al.
(2014). NBI cystoscopy in routine urological practice: From better vision to
improved therapeutic management. Journal of Medicine and Life, 7(2),
282-286.
[6].
Shruthi,
H. P., & Rangaswamy, R. (2015). Spectrum of lesions in urinary bladder
biopsies: A histopathological study. International Journal of Health
Sciences and Research, 5(5), 144-152.
[7].
Grandhi,
B., Byna, S. S. R., Shanthi, V., Vydehi, B. V., Rao, N. M., & Goel, A.
(2016). Histopathological spectrum of urothelial lesions. IOSR Journal of
Dental and Medical Sciences, 15(6), 4-7.
[8].
Shah,
P. Y., Nanavati, M., Patel, R. G., & Goswami, H. M. (2016). Spectrum of
lesions in urinary bladder: A histopathological study. International
Journal of Current Research and Review, 8(4), 19-24.
[9].
Srikousthubha,
Sukesh, Raghuveer, C. V., & Hingle, S. (2013). Profile of lesions in
cystoscopic bladder biopsies: A histopathological study. Journal of
Clinical and Diagnostic Research, 7(8), 1609-1612.
[10].
Chinnaswamy,
R., Krishnamoorthy, S., Joseph, L., Kumaresan, N., & Ramanan, V. (2016).
Clinico-pathological study of bladder cancer in a tertiary care centre of South
India and impact of age, gender, and tobacco in causing bladder cancer: A
single centre experience. International Journal of Scientific Study,
3(10), 72-77.
[11].
Laishram,
R. S., Kipgen, P., Laishram, S., Khuraijam, S., & Sharma, D. C. (2012).
Urothelial tumors of the urinary bladder in Manipur: A histopathological
perspective. Asian Pacific Journal of Cancer Prevention, 13,
2477-2481.
[12].
Anita,
S., & Manglesh, A. S. (2018). Spectrum of lesions in urinary bladder: A
histopathological study. Journal of University College of Medical Sciences,
6(2), 18.
[13].
Choi,
W., Oh, B. H., Kim, M. S., et al. (2014). Identification of distinct basal and
luminal subtypes of muscle-invasive bladder cancer with different sensitivities
to frontline chemotherapy. Cancer Cell, 25(2), 152-165.
[14].
Cancer
Genome Atlas Research Network. (2014). Comprehensive molecular characterization
of urothelial bladder carcinoma. Nature, 507, 315-322.
[15].
Damrauer,
J. S., Robinson, D. R., Korkan, M., et al. (2014). Intrinsic subtypes of
high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings
of the National Academy of Sciences of the United States of America,
111(13), 3110-3115.
[16]. Dadhania, V., Weiner, D. M., Geynisman, D. M., et al.
(2016). Meta-analysis of the luminal and basal subtypes of bladder cancer and
the identification of signature immunohistochemical markers for clinical use. EBioMedicine,
12, 105-117.
[17].
Miyamoto,
H., Shariat, S. F., Kuroda, N., et al. (2012). GATA binding protein 3 is
down-regulated in bladder cancer yet strong expression is an independent
predictor of poor prognosis in invasive tumor. Human Pathology, 43(12),
2033-2040.
[18].
Aparna,
C., Thumma, R. R., Devi, C. P., Vanapalli, S. V. R. L. J., & Mounika, T. D.
N. (2016). Histopathological spectrum of urothelial lesions: Experience of a
single tertiary care institute. International Journal of Contemporary
Medical Research, 3(6), 1731-1733.
[19].
Lerner,
S. P., McConkey, D. J., Hoadley, K. A., Chan, K. S., Kim, W. Y., Radvanyi, F.,
Höglund, M., & Real, F. X. (2016). Bladder cancer molecular taxonomy:
Summary from a consensus meeting. Bladder Cancer, 2(1), 37-47.
https://doi.org/10.3233/BLC-150037
[20].
Hashmi,
A. A., Hussain, Z. F., Irfan, M., Edhi, M. M., Kanwal, S., Faridi, N., &
Khan, A. (2018). Cytokeratin 5/6 expression in bladder cancer: Association with
clinicopathologic parameters and prognosis. BMC Research Notes, 11(1),
207. https://doi.org/10.1186/s13104-018-3319-4
[21]. Jung, S., Wu, C., Eslami, Z., Tanguay, S., Aprikian,
A., Kassouf, W., & Brimo, F. (2014). The role of immunohistochemistry in
the diagnosis of flat urothelial lesions: A study using CK20, CK5/6, P53,
CD138, and HER2/Neu. Annals of Diagnostic Pathology, 18(1), 27-32.
https://doi.org/10.1016/j.anndiagpath.2013.10.006
[22].
Kaufmann,
O., Fietze, E., Mengs, J., & Dietel, M. (2001). Value of p63 and
cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis
of poorly differentiated and undifferentiated carcinomas. American Journal
of Clinical Pathology, 116(6), 823-830.
https://doi.org/10.1309/21TW-2NDG-JRK4-PFJX
[23].
Sikic,
D., Keck, B., Wach, S., Taubert, H., Wullich, B., Goebell, P. J., Kahlmeyer,
A., Olbert, P., Isfort, P., Nimphius, W., Hartmann, A., Giedl, J., & Bridge
Consortium. (2017). Immunohistochemical subtyping using CK20 and CK5 can
identify urothelial carcinomas of the upper urinary tract with a poor
prognosis. PLoS ONE, 12(6), e0179602.
https://doi.org/10.1371/journal.pone.0179602
[24].
Wang,
C. C., Tsai, Y. C., & Jeng, Y. M. (2019). Biological significance of GATA3,
cytokeratin 20, cytokeratin 5/6, and p53 expression in muscle-invasive bladder
cancer. PLoS ONE, 14(8), e0221785.
https://doi.org/10.1371/journal.pone.0221785
[25].
Elzohery, N., Ismael, N. S., Khairy, R.
A., & Soliman, S. A. M. (2021). Expression of GATA3 and cytokeratin 14 in
urinary bladder carcinoma (histopathological and immunohistochemical study). Open
Access Macedonian Journal of Medical Sciences, 9(A), 858-864. https://doi.org/10.3889/oamjms.2021.6740
[26].
Al-Sharaky,
D. R., Abdelwahed, M., Asaad, N., Foda, A., & Abdou, A. G. (2021).
Stratification of urinary bladder carcinoma based on immunohistochemical
expression of CK5, CK14, and CK20. Journal of Immunoassay and
Immunochemistry, 42(3), 236-251.
https://doi.org/10.1080/15321819.2020.1845726
[27].
Bejrananda,
T., Kanjanapradit, K., Saetang, J., & Sangkhathat, S. (2021). Impact of
immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression
on survival after radical cystectomy for muscle-invasive bladder cancer. Scientific
Reports, 11(1), 21186. https://doi.org/10.1038/s41598-021-00628-5
[28].
Ravanini,
J. N., Assato, A. K., Wakamatsu, A., & Alves, V. A. F. (2021). Combined use
of immunohistochemical markers of basal and luminal subtypes in urothelial
carcinoma of the bladder: Association with clinicopathological features and
outcomes. Clinics (São Paulo), 76, e2587.
https://doi.org/10.6061/clinics/2021/e2587
